A5101435028- Protein Degradation and Inhibitors
- Sarcoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Telomeres, Telomerase, and Senescence
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Health Systems, Economic Evaluations, Quality of Life
- Head and Neck Cancer Studies
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Esophageal and GI Pathology
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Multiple and Secondary Primary Cancers
- Lung Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Biomedical Ethics and Regulation
- Pancreatic and Hepatic Oncology Research
Japan Clinical Cancer Research Organization
2016-2025
University of Miyazaki
2011-2024
National Cancer Center
2015-2023
National Institute for Japanese Language and Linguistics
2023
National Clinical Research
2019-2023
Tokyo National Hospital
2018-2023
Toyota Motor Corporation (Switzerland)
2023
Eli Lilly (Japan)
2022
Aso Iizuka Hospital
2003-2020
Kumamoto University
2015-2020
Prior to publication of the Clavien-Dindo classification in 2004, there were no grading definitions for surgical complications either clinical practice or trials. This report establishes supplementary criteria this standardize evaluation postoperative trials.The Japan Clinical Oncology Group (JCOG) commissioned a committee. Members from nine study groups (gastric, esophageal, colorectal, lung, breast, gynecologic, urologic, bone and soft tissue, brain) specified experienced commonly their...
The aim of the study was to confirm noninferiority mesorectal excision (ME) alone ME with lateral lymph node dissection (LLND) in terms efficacy.Lateral pelvic metastasis is occasionally found clinical stage II or III lower rectal cancer, and LLND standard procedure Japan. alone, however, international surgical for cancer.Eligibility criteria included histologically proven cancer at II/III; main lesion located rectum, margin below peritoneal reflection; no enlargement; Peformance Status 0 1;...
PURPOSE The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m 2 ). However, whether weekly (40 ) yields comparable efficacy in LA-SCCHN unknown. PATIENTS AND METHODS In this multi-institutional open-label phase II/III trial, patients were randomly assigned to receive either or confirm noninferiority cisplatin. primary end point II was proportion completion, that III...
PURPOSE To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients uterine carcinosarcoma (UCS) expressing HER2. PATIENTS AND METHODS Patients recurrent UCS HER2 immunohistochemistry scores ≥1+ previously treated chemotherapy were included. assigned to HER2-high (immunohistochemistry score ≥2+; n = 22) or low 1+; 10) groups for primary exploratory...
Low-dose cisplatin and 5-fluorouracil (LDPF) chemotherapy with daily radiotherapy (RT) is used as an alternative chemoradiotherapy regimen for locally advanced esophageal carcinoma. We evaluated whether RT plus LDPF had advantage in terms of survival and/or toxicity over standard-dose (SDPF) this study. This multicenter trial included cancer patients clinical T4 disease unresectable regional lymph node metastasis. Patients were randomly assigned to receive (2 Gy/fraction, total dose 60 Gy)...
Recently, depletion of skeletal muscle mass (sarcopenia) has been linked to poor prognosis in several types cancers, but not investigated esophageal squamous cell carcinoma (ESCC). This retrospective study investigates the relationship between sarcopenia and clinical outcome ESCC patients treated by surgical resection or definitive chemoradiation therapy (dCRT). The was retrospectively conducted a single academic hospital Kumamoto, Japan, involved 325 (256 cases 69 dCRT cases) April 2005...
Surgery is the standard of care for T1bN0M0 esophageal squamous cell carcinoma (ESCC), whereas chemoradiotherapy (CRT) a treatment option. This trial aimed to investigate noninferiority CRT relative surgery ESCC.Clinical ESCC patients were eligible enrollment in this prospective nonrandomized controlled study versus CRT. The primary endpoint was overall survival, which determined using inverse probability weighting with propensity scoring. consisted an esophagectomy 2- or 3-field lymph node...
Etoposide plus cisplatin (EP) and irinotecan (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC).To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) patients with NEC the digestive system.This open-label phase 3 randomized clinical trial enrolled chemotherapy-naive aged 20 to 75 years who had recurrent unresectable (according 2010 World Health Organization classification system) arising from gastrointestinal...
Trastuzumab deruxtecan (DS-8201) is an antibody–drug conjugate composed of a humanized monoclonal anti-HER2 antibody, cleavable tetrapeptide-based linker and potent topoisomerase I inhibitor. The drug's efficacy has been proven in HER2-positive breast gastric cancers. rate HER2 positivity biliary tract cancer (BTC) reported to be 5–20%, case reports clinical trials have suggested that inhibitors might active BTC. Here we describe the rationale design phase II HERB trial will evaluate safety...
Abstract Intimal sarcoma is an extremely rare, life-threatening malignant neoplasm. Murine double minute 2 (MDM2) amplification observed in >70% of intimal sarcomas. Milademetan, MDM2 inhibitor, may provide clinical benefit this patient population. We conducted a phase Ib/II study patients with MDM2-amplified, wild-type TP53 as substudy large nationwide registry for rare cancers Japan. Milademetan (260 mg) was administered orally once daily 3 days every 14 days, twice 28-day cycle. Of...
PURPOSE Treatment options for patients with unresectable or recurrent biliary tract cancer (BTC) who progress on a gemcitabine-containing regimen are limited. In addition, the significance of anti–human epidermal growth factor receptor 2 (HER2) therapy in HER2-expressing BTC has not been sufficiently investigated. METHODS this phase II trial, participants from five institutions Japan were enrolled. Eligible had pathologically confirmed centrally HER2-positive (immunohistochemistry [IHC]3+...
BackgroundBRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib trametinib being standard treatments for certain cancers, their efficacy across various solid tumours remains unelucidated. The BELIEVE trial assessed the of with BRAF V600E/R or non-V600 mutations.MethodsBetween October 1, 2019, June 2022, at least 50 patients measurable seven without diseases examined were enrolled a subcohort (NCCH1901, jRCTs031190104). mutated tumour cases...
Mutations of calreticulin (CALR) are detected in 25–30% patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result proteins a novel C-terminal. We demonstrate CALR mutations activated signal transducer activator transcription 5 (STAT5) 293T cells the presence thrombopoietin receptor (MPL). Human megakaryocytic CMK11-5 erythroleukemic F-36P-MPL knocked-in showed increased growth acquisition cytokine-independent growth, respectively, accompanied by...